Neutralizing toxic oligomers
Meet us for partnering opportunities
Novel Alzheimer and amyloidosis treatment targets
Target oligomeric species using the crossbeta technology platform
Crossbeta Biosciences, Utrecht, the Netherlands
-
Video
Opportunities for partners -
News
27.01.2012 - Crossbeta Biosciences, Good Biomarker Sciences and U-Protein Express join forces.... -
Drug discovery services platform
Stable protein oligomers as drug targets -
Alzheimer's drug discovery
Novel treatment targets for Alzheimer’s and other misfolded protein diseases -
Video
Opportunities for investors -
Contact
+31 30 253 8823 
info@crossbeta.com